- Verona Pharma said it had commenced a dose-ranging trial to evaluate the efficacy and safety of a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease.

Verona Pharma was also developing a dry powder inhaler formulation of ensifentrine.

The Phase 2 trial using the MDI formulation had a randomized, double-blind, placebo-controlled, two-part design.

The said it expected to report data from the first part of the trial in the second half of 2019, with final data expected in the first quarter of 2020.

At 1:51pm: [LON:VRP] Verona Pharma PLC share price was +0.5p at 59.5p

Story provided by